

<b>UTILITY PATENT APPLICATION TRANSMITTAL</b> <i>(Only for new nonprovisional applications under 37 CFR 1.53(b))</i>		Attorney Docket No. <b>031896-029000</b>	
		First Inventor <b>Michael R. Bowman</b>	
		Title <b>COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING ASTHMA OR OTHER ALLERGIC OR INFLAMMATORY DISEASES</b>	
		Express Mail Label No. _____	
<b>APPLICATION ELEMENTS</b> See MPEP chapter 600 concerning utility patent application contents.		Mail Stop Patent Application Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	
1. <input type="checkbox"/> Fee Transmittal Form (e.g., PTO/SB/17) <i>(Submit an original and a duplicate for fee processing)</i> 2. <input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. 3. <input checked="" type="checkbox"/> Specification [Total Pages <b>73</b> ] <i>(preferred arrangement set forth below)</i> - Descriptive title of the invention - Cross Reference to Related Applications <i>(if applicable)</i> - Statement Regarding Fed sponsored R & D <i>(if applicable)</i> - Reference to sequence listing, a table, or a computer program listing appendix <i>(if applicable)</i> - Background of the Invention - Brief Summary of the Invention - Brief Description of the Drawings <i>(if filed)</i> - Detailed Description - Claim(s) - Abstract of the Disclosure 4. <input checked="" type="checkbox"/> Drawing(s) (35 U.S.C. 113) [ Total Sheets <b>24</b> ] 5. Oath or Declaration [ Total Pages <input type="checkbox"/> ] a. <input type="checkbox"/> Newly executed (original or copy) b. <input type="checkbox"/> Unsigned c. <input type="checkbox"/> Copy from a prior application (37 CFR 1.63(d)) <i>(for continuation/divisional with Box 18 completed)</i> i. <input type="checkbox"/> <b>DELETION OF INVENTOR(S)</b> Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b) 6. <input checked="" type="checkbox"/> Application Data Sheet. See 37 CFR 1.76		7. <input type="checkbox"/> CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix) 8. Nucleotide and/or Amino Acid Sequence Submission <i>(if applicable, all necessary)</i> a. <input checked="" type="checkbox"/> Computer Readable Form (CRF) b. Specification Sequence Listing on: i. <input type="checkbox"/> CD-ROM or CD-R (2 copies; IBM-PC compatible; MS-Windows; including "AM101023 Sequence Listing.ST25.txt" (_____ KB, created on _____) ii. <input checked="" type="checkbox"/> paper c. <input checked="" type="checkbox"/> Statements verifying identity of above copies	
<b>ACCOMPANYING APPLICATION PARTS</b>			
9. <input type="checkbox"/> Assignment Papers (cover sheet & document(s)) 10. <input type="checkbox"/> 37 CFR 3.73(b) Statement <input type="checkbox"/> Power of <i>(when there is an assignee)</i> Attorney 11. <input type="checkbox"/> English Translation Document <i>(if applicable)</i> 12. <input type="checkbox"/> Information Disclosure <input type="checkbox"/> Copies of IDS Statement (IDS)/PTO-1449 Citations 13. <input type="checkbox"/> Preliminary Amendment 14. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) <i>(Should be specifically itemized)</i> 15. <input type="checkbox"/> Certified Copy of Priority Document(s) <i>(if foreign priority is claimed)</i> 16. <input type="checkbox"/> Nonpublication request under 35 U.S.C. 122(b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent. 17. <input checked="" type="checkbox"/> Other: <b>Statement Pursuant to 37 C.F.R. Section          1.821(f)</b>			
18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76: <input type="checkbox"/> Continuation <input type="checkbox"/> Divisional <input type="checkbox"/> Continuation-in-part (CIP) of prior application No.: _____ Prior application information: Examiner _____ Group / Art Unit: _____			
For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation <u>can only</u> be relied upon when a portion has been inadvertently omitted from the submitted application parts.			
<b>19. CORRESPONDENCE ADDRESS</b>			
<input checked="" type="checkbox"/> Customer Number or Bar Code Label		or <input type="checkbox"/> Correspondence address below	
22204			
Name	Nixon Peabody LLP		
Address	401 Ninth Street, N.W.		
	Suite 900		
City	Washington	State	DC
Country	USA	Zip Code	20004
	Telephone	202-585-8000	Fax 202-585-8080
Name (Print/Type)	Thomas W. Cole	Registration No. (Attorney/Agent)	28,290
Signature	<i>Thomas W. Cole</i>	Date	March 04, 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re **PATENT** application of )  
*Michael R. BOWMAN et al.* ) Group Art Unit: To be Assigned  
Application No.: To be Assigned ) Examiner: To be Assigned  
Filed: March 04, 2004 ) Date: March 04, 2004  
For: COMPOSITIONS AND METHODS FOR )  
DIAGNOSING AND TREATING )  
ASTHMA OR OTHER ALLERGIC )  
OR INFLAMMATORY DISEASES )

**PETITION TO INCORPORATE COLOR DRAWINGS**  
**UNDER 37 C.F.R. 1.84(b)(2)**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Applicants hereby petition for the acceptance of the color drawings of Figures 1, 6, 8, and 9, in the instant application. These color drawings are necessary to show details of the invention that could not be adequately shown in black and white drawings or photographs.

Three sets of the color drawings consisting of Figures 1, 6, 8, and 9 are provided herewith along with one black and white copy of each drawing sheet. The Specification describes the color drawing in the Brief Description of The Drawings, as required by 37 C.F.R. 1.84(a)(2)(iv).

Applicants respectfully request that these photographs be accepted for printing in the instant application.

Respectfully submitted,

By: Thomas W. Cole  
Thomas W. Cole  
Registration No. 28,290

NIXON PEABODY, LLP  
401 9<sup>th</sup> Street, N.W.  
Suite 900  
Washington, DC 20004-2128  
(202) 585-8000